Analyst: New Eli Lilly drug doesn't throw Novo Nordisk's Ozempic curveball

Danish bank analyst Søren Løntoft from Sydbank estimates that Eli Lilly has presented a decent set of data for new drug tirzepatide, but hardly enough to outmatch Novo's Ozempic drug.

Photo: Darron Cummings/AP/Ritzau Scanpix

On Wednesday, US pharmaceutical company Eli Lilly presented another batch of decent trial results with the GIP/GLP-1 analog tirzepatide, which is comparable with Novo's semaglutide, marketed as Ozempic and Rybelsus, on several counts.

In the trial programs Surpass-3 and Surpass-5 Eli Lilly has compared tirzepatide with Novo's insulin Tresiba and with placebo, "trick" medicine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs